Total androgen blockade for metastatic cancer of the prostate
- PMID: 3149456
- DOI: 10.1097/00000421-198801102-00043
Total androgen blockade for metastatic cancer of the prostate
Abstract
This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical